What are the current treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients?
Best insight from top research papers
The current treatment guidelines for metastatic castration-resistant prostate cancer (mCRPC) in older, frail patients recommend the use of taxanes, androgen receptor signaling inhibitors (ARSIs), and poly (ADP-ribose) polymerase (PARP) inhibitors. Taxanes, such as docetaxel and cabazitaxel, are the most active chemotherapy drugs for mCRPC . ARSIs, including abiraterone and enzalutamide, have shown significant survival benefits in both pre- and post-docetaxel settings . In addition, PARP inhibitors, such as olaparib and rucaparib, have emerged as promising treatment options for mCRPC . It is important to note that treatment plans should be individualized based on each patient's overall health and social context, taking into consideration their goals and values . Furthermore, targeted interventions to improve treatment tolerance, such as assessing frailty, functional status, life expectancy, and treatment toxicity risk, can be used to optimize treatment outcomes in older, frail patients with mCRPC .
Answers from top 5 papers
More filters
| Papers (5) | Insight |
|---|---|
17 Citations | The provided paper does not mention specific treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients. |
| The paper does not provide specific treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients. | |
2 Citations | The provided paper does not specifically mention the current treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients. |
| The provided paper does not specifically mention the treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients. | |
13 Citations | The provided paper does not specifically mention the current treatment guidelines for metastatic castration-resistant prostate cancer in old, frail patients. |
Related Questions
What are the current treatment guidelines for pneumonia?5 answersThe current treatment guidelines for pneumonia emphasize the importance of appropriate empirical antibiotic therapy, considering local epidemiology. For severe community-acquired pneumonia (sCAP), international guidelines recommend evidence-based clinical practice for diagnosis, empirical treatment, and antibiotic therapy, following the GRADE approach. These guidelines address the need for clear recommendations in managing patients with sCAP, highlighting the significance of factors like national and local antimicrobial susceptibility data and patient characteristics in choosing empirical antibiotic therapy. Additionally, clinical recommendations for community-acquired pneumonia stress the selection of rational antibiotic therapy to ensure optimal clinical efficacy, reduced antibiotic resistance, and minimized side effects, with approval by the Ministry of Health of the Russian Federation in 2021.
What are the current guidelines for palliative care in the UK?5 answersCurrent guidelines for palliative care in the UK emphasize the importance of cultural safety, focusing on improving quality of life through symptom control, and providing support earlier in the disease process to avoid missed opportunities for palliative services. Palliative social workers play a crucial role in the UK, working with individuals of all ages, promoting social justice, and utilizing therapeutic skills to help patients and families make informed decisions. Additionally, estimates suggest that a significant proportion of deaths in the UK require palliative care, highlighting the ongoing need for comprehensive end-of-life support, especially considering the impact of the COVID-19 pandemic on palliative care needs.
What are the latest advances in the treatment of metastatic breast cancer?5 answersRecent advances in the treatment of metastatic breast cancer include the use of combination therapies and personalized medicine. For patients with estrogen-receptor (ER)-positive disease, the standard of care involves combination therapies with cyclin-dependent kinase 4/6 inhibitors, endocrine therapy, and PI3 kinase. In HER2-positive disease, fam-trastuzumab deruxtecan-nxki and tucatinib have shown improved outcomes. For triple-negative breast cancer, pembrolizumab, PARP inhibitors, and antibody-drug conjugates such as sacituzumab govitecan-hziy have demonstrated activity. Additionally, immunotherapy with pembrolizumab and atezolizumab, as well as PARP inhibitors olaparib and talazoparib in BRCA mutation carriers, have shown promise in patients with metastatic disease. These advancements in treatment options provide new opportunities for managing metastatic breast cancer and improving patient outcomes.
What are the current treatment options for de novo metastatic prostate cancer?5 answersThe current treatment options for de novo metastatic prostate cancer include combination therapies with androgen deprivation therapy (ADT) and either docetaxel or androgen receptor targeting agents (ARTAs) such as abiraterone, enzalutamide, apalutamide, or darolutamide. Triplet therapy with ADT, an androgen-receptor inhibitor, and docetaxel has shown to be most efficacious for selected patients with de novo, high-volume, metastatic, hormone-sensitive prostate cancer. Systemic therapeutic treatments, including chemotherapy with docetaxel, abiraterone, enzalutamide, and apalutamide, in addition to ADT, have demonstrated improved outcomes in patients with de novo oligometastatic hormone-sensitive prostate cancer. Local therapy of the primary tumor, such as radiotherapy or radical prostatectomy, has also been reported as feasible and safe treatment options for low-volume metastatic disease. Metastasis-directed therapy has shown to prolong outcomes in both de novo and recurrent metastatic prostate cancer, although data on survival are still limited.
What are the current recommendations for testosterone replacement therapy in men?5 answersTestosterone replacement therapy (TRT) is an important treatment option for men with low testosterone levels and symptomatic hypogonadism. Various formulations for exogenous TRT exist, including oral, buccal, intramuscular, transdermal, subdermal, and nasal ones. All approved testosterone replacement methods can restore normal serum testosterone concentrations and relieve symptoms in most hypogonadal men. The selection of the method depends on the patient's preference with advice from the physician. Dose adjustment is possible with most delivery methods but may not be necessary in all hypogonadal men. If fertility is desired in the near future, alternative pharmacologic therapies such as human chronic gonadotropin, selective estrogen receptor modulator, estrogen antagonist, or an aromatase inhibitor that stimulates endogenous testosterone production may be used. Clinicians must consider the unique characteristics of each patient and make the necessary adjustments in the management of late-onset hypogonadism to provide the safest and most beneficial results.
Is frailty associated with prognosis in cancer patients?5 answersFrailty is associated with prognosis in cancer patients. Studies on lung cancer patients, head and neck cancer patients, and colorectal cancer patientshave shown that frailty at diagnosis is linked to higher all-cause mortality rates. Frail patients have a higher risk of mortality compared to non-frail patients. Frailty is also associated with worse overall health, lower body mass index, and higher rates of complications. Frail patients are more likely to require postoperative blood transfusions, experience delirium, and need support outside the home. The prevalence of frailty in cancer patients ranges from 45% in lung cancer patientsto 17.8% in lung cancer patients. These findings highlight the importance of assessing frailty in cancer patients to predict prognosis and guide treatment decisions.